Abstract:An effective anti-tumor immune response requires the coordinated action of the innate and adaptive phases of the immune system. Critical processes include the activation of dendritic cells to present antigens, produce cytokines including type I interferons, and express multiple costimulatory ligands; induction of a productive T cell response within lymph nodes; migration of activated T cells to the tumor microenvironment in response to chemokines and homing receptor expression; and having effector T cells gain access to antigen-expressing tumor cells and maintain sufficient functionality to destroy them. However, tumors can become adept at escaping the immune response, developing multiple mechanisms to disrupt key processes. In general, tumors can be assigned into two different, major groups depending on whether the tumor there is an ‘inflamed’ or ‘non-inflamed’ tumor microenvironment. Improvements in our understanding of the interactions between the immune system and cancer have resulted in the development of various strategies to improve the immune-mediated control of tumors in both sub-groups. Categories of major immunotherapeutic intervention include methods to increase the frequency of tumor antigen-specific effector T cells in the circulation, strategies to block or uncouple a range of immune suppressive mechanisms within the tumor microenvironment, and tactics to induce de novo immune inflammation within the tumor microenvironment. The latter may be particularly important for eliciting immune recognition of non-inflamed tumor phenotypes. The premise put forth in this review is that synergistic therapeutic effects in vivo may be derived from combination therapies taken from distinct “bins” based on these mechanisms of action. Early data in both preclinical and some clinical studies provide support for this model. We also suggest that optimal application of these combinations may be aided by appropriate patient selection based on predictive biomarkers.

Deciphering and Reversing Tumor Immune Suppression

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Immunosuppressive Strategies that are Mediated by Tumor Cells

Tumor Immune Checkpoints and Their Associated Inhibitors

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

Tumor-derived Exosomes and Antitumor Immunity

Immune resistance orchestrated by the tumor microenvironment

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

Immunoregulatory T cells in tumor immunity

Cracking the Codes behind Cancer Cells' Immune Evasion

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Precise Spatiotemporal Interruption of Regulatory T-cell-Mediated CD8(+) T-cell Suppression Leads to Tumor Immunity

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment

Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?

Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

Reversing T-cell Dysfunction and Exhaustion in Cancer

How to Detour Treg Cells in T Cell-Based Antitumor Immune Therapy

Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy

Rational combinations of immunotherapeutics that target discrete pathways